Complete clearance · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes complete clearance compared with placebo (very low certainty).
1 finding from 1 review
Recurrence · AGW in non‐immunocompromised adults
Imiquimod showed no clear difference in recurrence during compared with any other patient‐applied treatment (low certainty).
1 finding from 1 review
Any local reactions during therapy · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes any local reactions during therapy compared with any other patient‐applied treatment (very low certainty).
1 finding from 1 review
Any systemic reactions during therapy · AGW in non‐immunocompromised adults
Imiquimod may leads to lower any systemic reactions during therapy compared with any other patient‐applied treatment (low certainty).
1 finding from 1 review
Complete clearance · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes complete clearance compared with any other provider‐administered treatment (very low certainty).
1 finding from 1 review
Recurrence · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes recurrence during compared with any other provider‐administered treatment (very low certainty).
2 findings from 1 review
Pain during therapy · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes pain during therapy compared with any other provider‐administered treatment (very low certainty).
1 finding from 1 review
Any local reactions during therapy · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes any local reactions during therapy compared with any other provider‐administered treatment (very low certainty).
1 finding from 1 review
Partial clearance · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes partial clearance compared with placebo (very low certainty).
1 finding from 1 review
Recurrence · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes recurrence during compared with placebo (very low certainty).
1 finding from 1 review
Appearance of new warts during treatment · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes appearance of new warts during treatment compared with placebo (very low certainty).
1 finding from 1 review
Any local reactions during therapy · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes any local reactions during therapy compared with placebo (very low certainty).
1 finding from 1 review
Any systemic reactions during therapy · AGW in non‐immunocompromised adults
Imiquimod showed no clear difference in any systemic reactions during therapy compared with placebo (low certainty).
1 finding from 1 review
Pain during therapy · AGW in non‐immunocompromised adults
Imiquimod may leads to higher pain during therapy compared with placebo (low certainty).
1 finding from 1 review
Complete clearance · AGW in non‐immunocompromised adults
It is very uncertain whether imiquimod changes complete clearance compared with any other patient‐applied treatment (very low certainty).
1 finding from 1 review
Partial clearance · AGW in non‐immunocompromised adults
Imiquimod showed no clear difference in partial clearance compared with any other patient‐applied treatment (low certainty).
1 finding from 1 review